Treos Bio Limited, which is developing precision peptide cancer vaccines coupled with companion diagnostics, today announced it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization. As part of the agreement, PPD® Biotech, a PPD service dedicated to biotech and small to mid-sized pharmaceutical companies, will manage Treos Bio’s first-in-man study of its lead therapeutic cancer vaccine for metastatic colorectal cancer. This study will be conducted in the United States and Europe.

Treos Bio, Ltd., which is developing precision cancer immunotherapies paired to companion diagnostics, today announced it completed an $8 million funding through a group of private investors.